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Chemotherapy-induced intestinal mucositis is characterized by pain and a pro-inflammatory
tissue response. Rat models are frequently used in mucositis disease investigations yet lit-
tle is known about the presence of pain in these animals, the ability of analgesics to amelio-
rate the condition, or the effect that analgesic administration may have on study outcomes.
This study investigated different classes of analgesics with the aim of determining their anal-
gesic effects and impact on research outcomes of interest in a rat model of mucositis.
Female DA rats were allocated to 8 groups to include saline and chemotherapy controls
(n = 8). Analgesics included opioid derivatives (buprenorphine; 0.05mg/kg and tramadol
12.5mg/kg) and NSAID (carprofen; 15mg/kg) in combination with either saline or 5-Fluoro-
uracil (5-FU; 150mg/kg). Research outcome measures included daily clinical parameters,
pain score and gut histology. Myeloperoxidase assay was performed to determine gut
inflammation. At the dosages employed, all agents had an analgesic effect based on beha-
vioural pain scores. Jejunal myeloperoxidase activity was significantly reduced by bupre-
norphine and tramadol in comparison to 5-FU control animals (53%, p = 0.0004 and 58%,
p = 0.0001). Carprofen had no ameliorating effect on myeloperoxidase levels. None of the
agents reduced the histological damage caused by 5-FU administration although tramadol
tended to increase villus length even when administered to healthy animals. These data
provide evidence that carprofen offers potential as an analgesic in this animal model due to
its pain-relieving efficacy and minimal effect on measured parameters. This study also sup-
ports further investigation into the mechanism and utility of opioid agents in the treatment of
chemotherapy-induced mucositis.
Introduction
Chemotherapy represents the first-line approach for cancer treatment, yet side-effects remain
significant. One such side-effect is mucositis, which results from a series of biological events
initiated by the epithelial cell response to cytotoxic damage [1]. Certain cytotoxic drugs are
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more commonly associated with mucositis development; the chemotherapy drug 5-fluoroura-
cil is one such agent [2]. Mucositis affects all mucous-membrane covered surfaces from the
mouth to the rectum, and remains the main dose limiting factor in cancer treatment [3, 4].
Mucositis is thought to be the resultant effect of a range of cytokine-mediated events culmi-
nating in mucosal atrophy and ulceration [5]. Epithelial sloughing, mucosal inflammation and
ulceration activate nociceptors causing a direct pain response [6]. Additionally, pain may arise
as a sequela of other gastrointestinal events such as abdominal bloating or a change in bowel
pattern [7]. Accordingly, patients typically require potent opioid analgesics for pain control
during extended periods of hospitalisation [6].
Rats are frequently used as models in alimentary mucositis disease investigations, in order
to elucidate pathogenesis of the condition or to trial new therapeutics [8]. It has previously
been demonstrated that rats with chemotherapy-induced mucositis undergo pathophysiologi-
cal changes, [9, 10] and exhibit behavioural signs indicative of pain [11]. However, analgesic
use is never reported in publications involving animal models of mucositis. It is therefore
unknown if analgesics commonly used in laboratory animal practice are efficacious against the
pain evoked by mucositis, or whether they impact on commonly measured experimental out-
comes, and hence would confound future study interpretation.
Consequently, the current study employed a rat model of mucositis induced by 5-Fluoro-
uracil to characterize the effect of three clinically relevant veterinary analgesics on the affective
component of the pain response, gut mucosal architecture and inflammatory response. Agents
chosen were: buprenorphine, a partial μ opiate agonist, [12] with moderate analgesic effect and
fewer side-effects than pure μ agonists [13]; tramadol, an ‘atypical’ opioid analgesic which
exerts its action via both opioid (μ receptor) and non-opioid (inhibition of monoamine uptake)
mechanisms [14]; and the selective COX-2 inhibitor Non-Steroidal Anti-Inflammatory Drug
(NSAID), carprofen [15].
Materials and Methods
Animals and Experimental Design
Female Dark Agouti rats (110-140g, n = 64) were sourced from a barrier-maintained Specific-
Pathogen Free production facility (Laboratory Animal Services, the University of Adelaide,
Adelaide, SA, Australia). Female rats were selected for this study since they are commonly used
in mucositis disease investigations and thus results of this study would find general practical
applicability [8]. On arrival, animals were group-housed in standard open-top polycarbonate
rat cages of dimensions 415 mm x 260 mm x 145 mm (Tecniplast, NSW, Australia). Rats
remained in these cages for an acclimatisation period of 5 days with ad libitum access to pota-
ble reverse osmosis treated water and a standard rat chow (Speciality Feeds, Glenn Forest,
WA). Room temperature was maintained at 21–23°C with a 12 hr reversed light-dark cycle
(lights off at 0800). Red light was provided to facilitate making observations from video-records
in the darkness. Following acclimatisation, animals were transferred to individual housing in
metabolic cages (Tecniplast. Exton, PA, US). Ad libitum access to food and water continued in
these cages but the diet was changed to an 18% casein-based diet [9, 16] to be consistent with
previously published papers in this area. [9]
Rats were randomly allocated to eight groups (n = 8): Saline injection (0.9% NaCl w/v), car-
profen (15 mg/kg) + saline, buprenorphine (0.05 mg/kg) + saline, tramadol (12.5 mg/kg)
+ saline, 5-Fluorouracil (5-FU) injection carprofen (15 mg/kg) + 5-FU, buprenorphine
(0.05mg/kg) + 5-FU, tramadol (12.5 mg/kg) + 5-FU. Experimental design was standardized
with previous studies evaluating novel therapeutic agents for the treatment of chemotherapy-
induced mucositis [9, 17]. All animal handling and drug administration procedures were
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performed as described in reputable guidance documents [18]. Rats were metabolic-cage
housed on study days 0–9. Acclimatization to metabolic cages occurred on experimental days
0–2 with data recording commencing on day 3. On day 6, manually restrained animals received
an intraperitoneal injection of 5-FU (150 mg/kg; Mayne Pharma Pty, Ltd, Mulgrave, Vic, Aus-
tralia) or an equivalent volume of saline. At this time analgesic treatments were commenced
depending on group allocation. All analgesics were injected subcutaneously into the scapular
region. Analgesics were given as per clinical practice and were continued at 12 hourly intervals
for the remainder of the study (a total of 6 doses). Animals were continuously video-recorded
in their home metabolic cages using closed-circuit television (CCTV) cameras (OzSpy CLOC
600IR) mounted behind each cage (one camera per cage).
Body weight, food and water intake and urine output were measured daily. Rats were
humanely killed by overdose of CO2 on day 9 (72 hours after 5-FU or saline injection). Blood
was obtained via cardiac puncture and collected into lithium heparin coated blood collection
tubes. All visceral organs were weighed. Gastrointestinal organs were weighed following con-
tent removal by gentle expression using a smooth edged spatula on an ice-cooled slab. Lengths
of the duodenum, small intestine and colon were measured un-stretched. Sections (2 cm) of
the gastrointestinal organs were collected and placed in 10% buffered formalin for histological
analysis. Further (4 cm) samples were snap frozen in liquid nitrogen and stored at -80°C for
later biochemical analysis. Animal housing and experimental protocols were approved by the
Animal Ethics Committee of the University of Adelaide and conducted in accordance with the
provisions of the Australian Code for the Care and Use of Animals for Scientific Purposes [19].
Behavioural Data Analysis
Behavioural scoring was conducted on the continuously recorded home cage data by one per-
son in a blinded fashion using analysis software (Cowlog, University of Helsinki, Helsinki, Fin-
land) [20]. The occurrences of a number of behaviours previously shown to be associated with
abdominal pain were scored over a 10 minute period at each of 3 time-points in the dark phase
of the circadian cycle; 12 hours prior to 5-FU injection and 48 hr and 50 hours post-injection
[21, 22]. The latter two time points were selected to include an observation point just prior to
analgesic injection and 2 hours following injection. Frequency only, or frequency and duration,
was scored based on the characteristics of the behaviour being observed. The ethogram used is
illustrated in Table 1. Sampling method, behaviours scored and time points observed were
selected based on a previous exploratory study in which maximal frequency of pain behaviours
was demonstrated to occur at 48 hours post-chemotherapy injection [11].
Myeloperoxidase (MPO) Assay
Tissue samples (4 cm) of the jejunum and ileum were thawed on ice and homogenized with 1.5
mL of phosphate buffer (10 mM, pH 6.1) for 60 seconds until a homogenous solution was
obtained. Homogenized samples were kept at −80°C until required. MPO levels were deter-
mined using the assay described by Krawisz et al. 1984 [23]. Homogenates were thawed on ice
and centrifuged at 13000 g for 13 min. Following removal of the supernatant the cell pellets
were re-suspended in hexadecyltrimethyl ammonium bromide (0.5%, pH 6.0). Samples were
then vortexed for 2 min and centrifuged at 13000 g for 3 min. Supernatants were collected into
a 96- well plate and reacted with o-dianisidine. Absorbance was measured at 450 nm at 1 min
intervals for a period of 15 min using a microplate reader (Sunrise Microplate Reader, Tecan
Austria GmbH, Grodig, Austria). A pre-designed excel macro was used to calculate MPO activ-
ity. Activity was expressed as units MPO per gram of tissue.
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Blood Biochemistry
Blood samples were centrifuged at 4000 g for 6 min, the plasma supernatant removed and
immediately analyzed for biochemical parameters using Beckman Coulter reagents (Beckman
Coulter AU480, NSW, Australia) at a commercial diagnostic lab (Veterinary Diagnostics Labo-
ratory, The University of Adelaide, Australia). Analyses included albumin, alkaline phospha-
tase (ALP), alanine transaminase (ALT), amylase, Ca:P ratio, creatinine kinase, creatinine,
glucose, Na:K ratio, total protein and urea.
Histological Analysis
Tissue samples were fixed in formalin for 24 h and then placed in 70% ethanol. Transverse tis-
sue sections (4 μm) were embedded in paraffin wax, H&E stained and viewed using a light
microscope (Olympus CX-41; Olympus, Tokyo, Japan). The disease severity score was deter-
mined semi-quantitatively by scoring eight independent histological criteria. The method used
represented a slight modification of that described by Howarth et al. 1996 [24]. The criteria
scored were: villus blunting, crypt distortion, reduction in goblet cell number, dilation of lym-
phatics, thickening of the submucosa, thickening of the muscularis externa, enterocyte disrup-
tion and lymphocytic cell infiltration. Each criterion was scored from zero (normal) to three
(maximal damage) and expressed as a median score. Saline control rat intestinal tissue was
used as a baseline reference to grade the criteria. Villus heights and crypt depths (40 villi and
40 crypts per section) were determined in the jejunal and ileal sections using a light microscope
(Nikon, ProgRes1CS, Tokyo, Japan) and image ProPlus software version 5.1 (Media Cyber-
netics, Silver Spring MD, USA). All histological analyses were conducted in a blinded fashion.
Statistical Analyses
Statistical analyses were conducted using PASW 21 (SPSS, Inc., Chicago, IL, USA) and Mega-
stat Excel Add-In (version 10.2, McGraw-Hill Higher Education, New York, NY). Data were
tested for normality and homogeneity of variance using the Shapiro–Wilk test. Parametric data
were compared using one-way analysis of variance (ANOVA) with a Tukey's post-hoc test and
presented as means ± standard error of the mean. Disease severity score and serum biochemis-
try were analysed by a Kruskal-Wallis test with a MannWhitney U-test to determine between-
Table 1. Ethogram for in-cage behavioural analysis (adapted from Roughan and Flecknell, 2001 [21]).
Behaviour Description
Attend Movement vibrissae accompanying head lifting
Back Arch Arching of back (‘cat stretch’)
Abdominal Groom Grooming
High Rear Standing on hindlegs
Sleep Inactivity for > 90s
Sniff Movement of vibrissae
Stagger/fall Loss of balance whilst walking or falling whilst grooming
Stop Transient inactivity <90s
Horizontal Stretch Elongation of the body with paws reaching above head
Turn Turning without movement in any direction
Twitch Contraction of back muscles
Walk Walking
Writhe Lateral contortion of ﬂank muscles
Yawn Yawning
doi:10.1371/journal.pone.0158851.t001
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group significance. Rat behavioural data were also non-parametric and analyzed similarly with
both between, and within group comparisons made. Non-parametric data are shown as medi-
ans and ranges. Significance was determined at p< 0.05 with Bonferroni corrections made
where appropriate to account for multiple comparisons.
Results
Daily Metabolic Parameters and Bodyweight
Following saline or 5-FU injection there were significant differences between the groups in a
number of the clinical parameters recorded (Table 2; see also S1 File). In the analgesic control
groups receiving saline injection, both buprenorphine and tramadol resulted in a decrease in
bodyweight with no concomitant decrease in food consumption. Bodyweights of animals in
the remaining treatment groups demonstrated an increase. Buprenorphine administration
increased water intake and consequently urine output (Table 2).
Administration of 5-FU significantly reduced bodyweight and food intake compared to
saline injected rats (Table 2). In the rats administered either buprenorphine or tramadol in
combination with 5-FU the analgesic agents potentiated this weight loss compared to the 5-FU
control group ("72%, p = 0.005; "143%, p< 0.001 respectively). Again, notably, this body-
weight decrease was not accompanied by a significant decrease in food intake (p = 0.99 for
both analgesic agents). Buprenorphine and tramadol administration to 5-FU injected rats
increased water consumption in comparison to 5-FU control animals by 135% (p = 0.002) and
117% (p = 0.003) respectively. Correspondingly, urine output was increased in animals receiv-
ing these analgesics.
Behavioural Assessment Scoring
In general, the specific pain behaviours of interest were observed at low frequencies, hence the
behaviours that had previously been shown to increase in mucositis [11] were amalgamated to
form a composite pain score, as described previously [25, 26]. This score consisted of back
arch, horizontal stretch, stagger, twitch and writhe. Whilst it is known that metabolic cage
housing does evoke changes in animal behaviour [27, 28] the consistent use of these cages
across all treatment groups should have minimized any confounding influence of the cages
themselves on behavioural outcomes.
Table 2. Effects of analgesic agents on cumulative bodyweight change, food and water intake and urine output in saline-injected rats and in 5-FU





















0.18 ± 0.02 0.19 ± 0.04 0.43 ± 0.10* 0.26 ± 0.06 0.23 ± 0.03 0.29 ± 0.03 0.54 ± 0.10*† 0.50 ± 0.07*†
Mean Daily Food
Intake (g/gbw)
0.08 ± 0.01 0.06 ± 0.01 0.06 ± 0.01* 0.06 ± 0.01 0.03 ± 0.01* 0.03 ± 0.01* 0.03 ± 0.01* 0.02 ± 0.01*
Mean Daily Urine
Output (ml/gbw)
0.09 ± 0.01 0.20 ± 0.05* 0.21 ± 0.05* 0.10 ± 0.01 0.16 ± 0.02 0.16 ± 0.02 0.34 ± 0.07*† 0.49 ± 0.05*†
* indicates statistical signiﬁcance compared to saline at p < 0.05.
† indicates statistical signiﬁcance compared to 5-FU alone at p < 0.05.
§ Bodyweight change is expressed as the mean total % change calculated in relation to the baseline weight recorded at the time of saline/5-FU injection.
doi:10.1371/journal.pone.0158851.t002
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Whilst all analgesic agent-treated groups demonstrated significant decreases in score when
compared to animals that received 5-FU alone at either the 48 hour or 50 hour time point, with
the exception of buprenorphine (50 hours) these values were not significant in comparison to
saline controls alone (Fig 1; see also S2 File). However, on comparing scores within groups
between the time points a significant difference was only recorded with the 5-FU control ani-
mals between baseline and 48 hours (p = 0.01) indicating that in all other groups they either
experienced no change in pain level, or that pain was effectively treated.
There was less consistency in the frequency of performance of the other measured behav-
iours (Table 3; see also S2 File) and there was significant inter-animal variability. Key changes
included that high rearing increased between baseline and 50 hours in the 5-FU alone group
(p = 0.03) and sleep duration increased between baseline and 48 hours in the buprenorphine
treated animals with mucositis (p = 0.01). The converse was observed for tramadol treated ani-
mals (p = 0.03).
OrganWeights
In healthy analgesic control animals, carprofen increased liver weight by 12% in comparison to
saline alone control animals (p = 0.04). Alternately, buprenorphine decreased liver weight by
10% (p = 0.03, Table 4). Administration of 5-FU significantly reduced thymus weight by 60%
(p< 0.001) and spleen weight by 20% (p< 0.001) compared to saline-injected rats (Table 4).
Both buprenorphine and tramadol administration exacerbated the 5-FU induced decrease in
thymic weight. Carprofen elevated renal weights (~"20%, p 0.001) whilst the converse was
observed with tramadol (#12%, p = 0.01) compared to 5-FU control (Table 4; see also S1 File).
Administration of 5-FU had no effect on liver mass. Analogously, carprofen led to an increase
in liver weight (11%, p = 0.006) in comparison to 5-FU control animals, whilst tramadol
decreased liver weight (11%, p = 0.02). However, buprenorphine when co-administered with
5-FU failed to produce liver mass changes.
5-FU significantly reduced the gastrointestinal organ lengths such that a 9% reduction was
evident in the jejuno-ileum (p = 0.01) and an 11% reduction in the colon (p = 0.03) (Table 5;
see also S1 File). The analgesic agents had minimal moderating effect on organ lengths except
for tramadol which attenuated the reduction in colon length produced by 5-FU (p = 0.02).
However, all analgesic agents produced a reduction in weight of the jejuno-ileum when com-
pared to 5-FU controls. A similar effect was observed in colon weights although this did not
attain significance in the 5-FU + carprofen group (p = 0.08).
Serum Biochemistry
Serum biochemistry results are reported in Table 6. Not all biochemical parameters were avail-
able for the tramadol-treated groups. When compared with saline controls, 5-FU caused statis-
tically significant differences in creatinine kinase (CK) and creatinine values. However, these
changes were unlikely to be of clinical significance. Noteworthy changes included; the elevation
in creatinine in all 5-FU treated groups, and the depression in total protein in animals receiving
the combination of 5-FU and carprofen. The consistent depression in urea was likely to be
attributable to the specific analyzer used. It should be noted that serum biochemistry reference
ranges for Dark Agouti rats were not available.
Myeloperoxidase Activity
There was no significant difference in MPO activity in either the jejunum or ileum when anal-
gesics were administered to healthy control animals, indicating that the agents caused no
adverse effects on inflammation at the given dosages.
Analgesics in a Rat Model of Chemotherapy-InducedMucositis
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Injection of 5-FU caused a significant (p< 0.001) increase in MPO activity in the proximal
jejunum and ileum of 5-FU control (1046% and 412% respectively) compared to saline control
animals (Fig 2; see also S3 File). In the jejunum, both buprenorphine and tramadol caused a
highly significant decrease in MPO activity in comparison with chemotherapy-treated control
animals (53%, p = 0.0004 and 58%, p = 0.0001 respectively, Fig 2A). Analogously, in the ileum,
tramadol reduced MPO activity by 31% (p = 0.003) in comparison to 5-FU controls. However,
buprenorphine failed to have a similar ameliorating effect (p = 0.19, Fig 2B).
Histological Severity Score
The histological architecture of the jejunum and ileum was entirely consistent with previous
rat studies of mucositis, and included shortening of villi, crypt disruption, loss of goblet cells
and enterocyte disruption (Fig 3). Chemotherapy administration significantly increased disease
severity score in the proximal jejunum and ileum in all treated animals (Fig 4; see also S4 File)
in comparison with saline-injected control animals (p< 0.001 for all), thus determining that
Fig 1. Effect of analgesic agents on composite pain score prior to injection, and 48hr and 50 hours after injection; (A) saline
injection (B) 5-FU injection. The box plots represent the first and third quartiles, horizontal lines represent the median pain
score and the whisker ends represent 1.5 x inter-quartile range, X represent outlying points. * indicates p < 0.05 compared to
saline + no analgesic and † p < 0.05 compared to 5-FU + no analgesic between groups within the same time point. §
represents significant difference at p = 0.008 between time points within the same group.
doi:10.1371/journal.pone.0158851.g001
Table 3. Effect of analgesic agents on non-pain specific behaviours. Data are expressed as median (interquartile range) of behavioural frequency over


















High rear 0 (2) 0 (0) 1 (3.5) 0 (0) 0 (0)§
(base, 50)
0 (0)* 0 (2) 1(0.75)
Abdominal
groom
2.5 (4) 1 (0.5) 1 (1) 0 (0) 0.5 (2.5) 0 (0) 2.5 (2.5) 1 (0.75)
Stop 2 (3.5) 1 (1.5) 2 (3.5) 0 (3) 3.5 (2.25) 0 (0.5)† 3 (3.75) 6 (1.5)*
Sleep
Duration (s)
364 (563) 516 (237) 149 (295) 600 (185) 377 (230) 490 (179) 79 (247) 290 (219)
48 Hours
High rear 0 (0) 0 (0)§ (48,50) 0 (1) 0 (2.5) 0 (0.5) 0 (0) 0 (0) 0 (0)
Abdominal
groom
1 (2) 1 (1) 0 (2) 1 (1.5) 0.1 (2) 1.5 (3) 0 (0.5) 1 (1)




1 (0.75)† 4.5 (5.25)
Sleep
Duration
402 (333) 478 (129) 582 (597) 0 (194)* 402 (143) 177 (440) 543 (185)§ (base, 48) 0
(0)†§(base, 48)
50 Hours
High rear 1 (2) 1 (2.5) 0 (0) 0 (0) 1.5 (5.5) 0 (0.5) 0 (0.5) 0.5 (2.5)
Abdominal
groom
2 (0.75) 2 (4) 0 (0) 1 (2) 1 (1.75) 1 (1.5) 0 (0)*† 0.5 (1.5)
Stop 3 (2.25) 2 (2.5) 1 (2.5) 4 (5) 5.5 (3.75) 1.5 (2.5) 3 (3) 2.5 (5.25)
Sleep
Duration
46 (292) 157 (302) 534 (109) 415 (433) 98 (94) 366 (183) 337 (252) 63.5 (177)
* indicates statistical signiﬁcance at p < 0.05 compared to saline alone.
† indicates statistical signiﬁcance at p < 0.05 compared to 5-FU alone.
§ represents signiﬁcant difference between time points within the same group, superscript value shows the time points that are statistically different.
doi:10.1371/journal.pone.0158851.t003
Analgesics in a Rat Model of Chemotherapy-InducedMucositis
PLOS ONE | DOI:10.1371/journal.pone.0158851 July 27, 2016 8 / 19
the mucositis condition was present. The analgesic agents had no effect on histological severity
score in healthy animals or when given in conjunction with 5-FU (Fig 4).
Villus Height and Crypt Depth Measurements
Jejunal Effects. 5-FU injection caused a shortening of the villi in the jejunum (36%,
P<0.001) compared to no analgesic saline controls (Fig 5; see also S4 File). Tramadol had a
lengthening effect on villus height when administered with 5-FU, although this failed to attain
significance. Administration of 5-FU caused no general reduction in crypt depth.
Ileal Effects. Similarly, 5-FU caused a villus shortening in the ileum (40%, p = 0.005) com-
pared to no analgesic saline controls (Fig 5B). Tramadol, when administered in the presence of
5-FU had a lengthening effect on villus height. This lengthening normalized villus heights
towards values in saline treated (219 ± 18 v 270 ± 43 μm, respectively, p = 0.18, Fig 5B). How-
ever, it should be noted that the 5-FU + tramadol villus height values were not significant with
respect to the 5-FU control group (p = 0.12, Fig 5B). Contrary to the results observed for jejunal
tissue, 5-FU caused a general reduction in crypt depth when compared with that of saline con-
trol animals.
Table 4. Effects of analgesic agents on visceral organ weights of female Dark Agouti rats 72 hr after 5-FU or saline injection. Organ weights were

















Thymus 20 ± 1 20 ± 2 17± 1 20 ± 1 8 ± 1* 8 ± 1* 5 ± 1*† 6 ± 1*†
Liver 393 ± 12 440 ± 9* 357 ± 6* 389 ± 22 388 ± 1 429 ± 9*† 381 ± 9 347 ± 9*†
Spleen 21 ± 1 23 ± 1* 23 ± 1 21 ± 1 17 ± 1* 18 ± 1* 15 ± 1* 16 ± 1*
Left Kidney 41 ± 1 47 ± 1* 42 ± 1 41 ± 2 44 ± 1 50 ± 1*† 47 ± 2* 39 ± 2†
Right
Kidney
43 ± 1 48 ± 1* 43 ± 1 42 ± 2 45 ± 1 50 ± 1*† 49 ± 1* 40 ± 1†
Adrenal
Glands
2 ± 0.1 2 ± 0.3 2 ± 0.1 2 ± 0.1 2 ± 0.1 3 ± 0.1 3 ± 0.1 3 ± 0.1
* indicates statistical signiﬁcance at p < 0.05 compared to saline alone.
† indicates statistical signiﬁcance at p < 0.05 compared to 5-FU alone.
doi:10.1371/journal.pone.0158851.t004
Table 5. Effects of analgesic agents on gastrointestinal organ weights and lengths of female Dark Agouti rats 72 hr after 5-FU or saline injection.



















300 ± 10 246 ± 6* 224 ± 10* 229 ± 10* 250 ± 6* 223 ± 3*† 200 ± 4*† 200 ± 8*†




70 ± 10 64 ± 2* 65 ± 3 63 ± 5* 70 ± 3 67 ± 2 62 ± 3*† 60 ± 3*†
length 14.4 ± 0.7 14.3 ± 0.4 14.9 ± 0.5 15.1 ± 0.6 12.8 ± 0.6* 11.0 ± 0.2* 12.7 ± 0.5* 14.4 ± 0.4†
* indicates statistical signiﬁcance at p < 0.05 compared to saline alone.
† indicates statistical signiﬁcance at p < 0.05 compared to 5-FU alone.
doi:10.1371/journal.pone.0158851.t005
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Discussion
This study represents the first published investigation into analgesics administered to rats with
experimentally-induced mucositis. The non-use of analgesia in these models potentially poses
an ethical issue. However, an ethical issue also arises if an administered analgesic confounds
data interpretation, resulting in misleading results and unnecessary study repetition. The cur-
rent study indicated that all analgesics tested were efficacious against rat nociceptive behaviour.
However, the opioid agonists had the potential to confound interpretation of study results due
to an anti-inflammatory action. Therefore, in mucositis studies in which myeloperoxidase
activity and histological parameters are the research outcomes of interest, carprofen is the pre-
ferred analgesic refinement.
Indeed, the opioid agents had more striking effects on the daily metabolic parameters and
bodyweight than the NSAID. Importantly, bodyweight decreased after administration of either
buprenorphine or tramadol in healthy animals, and these agents potentiated weight loss in ani-
mals with mucositis. This finding is likely to have arisen due to appetite suppression as a result
of excess opioid activity, [29] postulated to be due to increased sedation or a nauseating effect.
However, we failed to consistently demonstrate a similar decrease in food consumption in ani-
mals treated with these agents. The increase in drinking behaviour was expected since it is well
established that μ-receptor activation leads to increased water intake, [30] although activation
of this receptor also tends to lead to urinary retention, [31] rather than an increase in urination
Table 6. Effects of analgesic agents on blood biochemistry values of female Dark Agouti rats 72 hr after 5-FU or saline injection. Data are
expressed as median values with experimental group range in brackets. Shaded results are outside references range values given by Giknis and Clifford,
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(18–42)











451.0 (389–550) - NA
Ca:P ratio 0.8 (0.6–
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0.8 (0.7–0.8) 0.7 (0.5–0.9) - 0.9 (0.5–
1.2)






























10 (7–13) 12.0 (7–13)*† - 7.3 (3–
10)
9.5(7–12) 9.5 (6–16) † - 4.2–9.7
Na:K ratio 22.4
(18–26)
20.8 (20–29) 20.4 (18–23) † - 24.6
(20–30)











56.5 (42–66) - 55–77
Urea (mmol/L) 5.0 (4–6) 5.0 (4–5) 5.5 (5–9) 6.0 (5–7) 4.3 (3–
7)
5.0 (4–6) 4.1 (4–6) * 7.3 (5–8) *† 13.2–
27.1
* indicates statistical signiﬁcance at p < 0.05 compared to saline alone.
† indicates statistical signiﬁcance at p < 0.05 compared to 5-FU alone.
doi:10.1371/journal.pone.0158851.t006
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Fig 2. Effect of analgesic agents on myeloperoxidase (MPO) activity in the jejunum (A) and ileum (B) 72 hr after either saline
or 5-FU injection. Data are expressed as mean (MPO units/g tissue) ± SEM. * indicates p < 0.05 compared to saline + no
analgesic and † p < 0.05 compared to 5-FU + no analgesic.
doi:10.1371/journal.pone.0158851.g002
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as demonstrated in the current study. The partial selectivity for this receptor by buprenorphine,
and low receptor affinity by tramadol [32] therefore present significant clinical advantages of
these drugs.
Fig 3. Representative photomicrographs (x 100) of the proximal jejunum sections stained with haematoxylin
and eosin in animals treated with saline alone (A), 5-FU alone (B), 5-FU + carprofen (C), 5-FU + buprenorphine
(D), 5-FU + tramadol (E).
doi:10.1371/journal.pone.0158851.g003
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The analysis of occurrence of specific pain behaviours in rats is a well-validated pain assess-
ment technique [21, 25, 33]. However, to date the applicability of the technique to models of
chemotherapy-induced mucositis has only been reported once [11]. In the current study, intra-
group differences across time were only evident in the 5-FU alone treated animals. There are
two explanations for this finding; either 1) no pain was experienced by animals in all other
groups and hence no change in score yielded, or 2) pain was experienced by animals with
mucositis and was effectively managed at these time-points, hence no change in score was
recorded. The latter interpretation is preferred for the 5-FU treated groups since the daily met-
abolic parameters and bodyweight data suggested that pathophysiological processes associated
with mucositis development were occurring. The behavioural data provide evidence for the
analgesics being present in plasma at a pharmacologically active level. This would however
require confirmatory pharmacokinetic determination. Furthermore, by this interpretation it is
concluded that, as previously determined, [21] the behaviours were truly pain-specific and not
modified by drug-induced states such as sedation. Nevertheless, these conclusions are
advanced cautiously since inter-group comparisons did not yield statistically significant differ-
ences between the chemotherapy-treated groups and saline control animals. However, given
the inherent inter-individual variability in behaviour performance, and the subjective nature of
the pain experience, comparison of values for the same animals across time may yield more
accurate and relevant results. Use of less manually intensive automatic home-cage monitoring
in future studies would allow comparison of a greater number of individuals at more time
points to confirm these conclusions [34].
There is a significant body of literature demonstrating that opioids modulate immune
responses [35]. Chronic administration of opioids to rodents has been demonstrated to lead to
thymic and splenic atrophy, [36–38] and elevation of CD4+/CD8+ ratios, [38] yet other studies
in rats have demonstrated an increase in spleen weight [39]. Such effects may be brought about
through direct suppression of natural killer cell activity via opiate receptors, or indirectly
through modulating cytokine release, [40] or induction of corticosteroids [41]. However,
buprenorphine has minimal immunosuppressive action [42, 43]. Since the splenic weight
decrease reported in the current study only occurred when co-administered with 5-FU there
may have been a synergistic effect, possibly driven via the chemotherapy-induced inflamma-
tory response, and the consequent Hypothalamic Pituitary Axis induced increase in corticoste-
rone, [44] or as a direct immunosuppressive effect of 5-FU. Consistent with our results, opioids
have previously been shown to decrease liver weights and increase kidney weights in vivo [39].
A decrease in hepatic vacuolization due to reduced food intake and hence glycogen storage
may explain the former finding [39]. The increase in renal and hepatic weight in carprofen-
treated animals is postulated to be a result of the drug clearance activities of these organs. It is
noteworthy that despite the previously referred to changes in organ weights, serum biochemis-
try confirmed there were no organ functional changes. Opioids tend to contract intestinal mus-
cle via direct activation of muscle cells, [45] or depression of nitric oxide release from enteric
neurons [46]. The finding of an increased colon length in the tramadol group is therefore
inconsistent but may reflect the differential selectivity of buprenorphine and tramadol for
the μ-opioid receptor.
Fig 4. Effects of analgesic agents on disease severity score in the jejunum (A) and ileum (B) 72 hr after either
saline or 5-FU injection. The severity scores were rated based on 8 parameters on different layers of
intestinal tissues. The box plots represent the first and third quartiles, horizontal lines represent the median
disease severity score and the whisker ends represent the maximum and minimum score. * indicates
p < 0.05 compared to saline + no analgesic.
doi:10.1371/journal.pone.0158851.g004
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Myeloperoxidase enzyme levels provide a measure of neutrophil influx and hence acute
inflammation [23]. Administration of the opioid analgesics had an anti-inflammatory effect as
evidenced through the substantial reduction in myeloperoxidase activity. This effect is assumed
to be as a result of the μ-receptor agonism since a similar effect has been noted previously [47].
This is of interest since opioid receptor agonists are generally assumed to have poor, or at least
misunderstood anti-inflammatory action [48]. To our knowledge, this is the first report of this
finding in chemotherapy-induced mucositis. In order to confirm this mechanism and deter-
mine the magnitude of it future studies should incorporate a μ- receptor antagonist agent.
Interestingly, the NSAID carprofen failed to attenuate the MPO response. This attests to the
selectivity of NSAID agents in preventing the production of inflammatory mediators such as
prostaglandins and leukotrienes via inhibition of the cyclooxygenase pathway [49]. However,
phagocytosing polymorphonuclear leucocytes produce H2O2 and chloride. The interaction
between H2O2 and chloride ions with MPO releases oxidant products. These oxidant products
are likely to be important inflammatory mediators [49]. Therefore, in spite of the blockade of
cyclooxygenase by NSAIDs, an inflammatory effect could still be produced via this alternate
oxidant pathway [49]. Therefore the ideal NSAID would not only have effects on the cyclooxy-
genase pathway, but anti-oxidant/free radical scavenging ability in addition. Whilst it has been
demonstrated that a range of NSAIDS target polymorphonuclear MPO via their free radical
scavenging effects, [49] our data suggest that carprofen was unable to exert this effect. Since,
myeloperoxidase activity is commonly used to measure therapeutic effect in trials of new thera-
peutic agents against mucositis, carprofen is rendered the drug of choice by this finding.
Despite, the beneficial reduction in MPO activity caused by the opioid agents, in the current
study, there was no corresponding decrease in histological severity score. However, tramadol
as the most efficacious agent in reducing MPO, showed a trend towards restoration of villus
height. It is noteworthy that this effect also occurred in healthy animals and is previously unre-
ported. In order to fully understand the inflammatory processes occurring in chemotherapy-
induced mucositis, their relation to histological repair and synergism between therapeutics,
future studies should investigate a range of inflammatory markers such as the pro-inflamma-
tory cytokines and cyclooxygenase activity.
Mechanisms of pain production by cytotoxic agents in gastrointestinal mucositis are poorly
understood, [50] yet pain remains one of the key dose-limiting factors for patients [51]. How-
ever, research effort in this area is likely to increase since the discovery that: 1) chemotherapy-
related hyperalgesia can be reversed by immunomodulatory agents [51]; and 2) there is a high
level of μ-opioid receptor expression in the intestinal tract, particularly during inflammation
[47]. Therefore, the ability to reliably measure affective pain as opposed to nociception is a
much needed animal model refinement. This study has indicated that behavioural pain assess-
ment scoring may be one such tool but does require further validation. Our data do however
raise some concerns with the ability of the model to replicate the human mucositis condition; if
human patients frequently require morphinomimetic agents to control pain, [52] yet rat pain
is controlled by less potent opioids or NSAIDs, is the subjective pain experience of both these
species too different to reconcile or, is there a possibility that partial opioid agonists, NSAIDs,
or a combination thereof, are under-utilized in human oncologic practice.
In conclusion, this study has provided evidence that carprofen is efficacious against pain,
and produces minimal interference with research outcomes, in a rat model of chemotherapy-
Fig 5. Effects of analgesic agents on villus height and crypt depth in the jejunum (A) and ileum (B) 72 hr after
either saline or 5-FU injection. VH = villus height, CD = crypt depth. Data are expressed as mean ± SEM. *
indicates p < 0.05 compared to saline + no analgesic and † p < 0.05 compared to 5-FU + no analgesic.
doi:10.1371/journal.pone.0158851.g005
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induced mucositis. Furthermore, the identification of intestinal anti-inflammatory activity
of μ- receptor opioid agonists supports further pre-clinical investigation into opioid agents
with non-traditional pharmacological actions, such as partial agonists, atypical agents, or
peripherally-acting agents [47].
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